By: Steve Deal
As you may be aware, NovoLog (insulin aspart) is the new rapid-acting insulin analog from Novo Nordisk Pharmaceuticals, Inc. On paper, its action is supposed to be similar to Lilly’s Humalog (insulin lispro). However, my experience, as well as the experiences of other people I’ve talked to who are using it in pumps, is very different.
When I first started using NovoLog with my pump, my control was in range, though perhaps a bit too tight. Soon, however, I began to have very frequent hypoglycemia after meals as well as between meals when my basal rate was the only thing controlling my blood glucose. (Three weeks before beginning to use NovoLog, I had fasted to ensure that my basal rates were set properly, and they were.)
To prevent hypoglycemia, I’ve had to make two adjustments to be sure that NovoLog fits my diabetes routine. First, I cut my basal rates by 0.1 unit per hour for the entire day. Second, I now take less insulin per carbohydrate choice for meals.
This, of course, is only one person’s experience; I have seen no published research data that would confirm it. Nevertheless, as mentioned, I have spoken to other people who are experiencing the same effects.
Is this experience good or bad? Well, as far as I’m concerned, any time you can take less insulin and reach the same goal, that is a good thing.